The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018.

The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018.

Publication date: May 10, 2019

The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.

Open Access PDF

Ascierto, P.A., Bruzzi, P., Eggermont, A., Hamid, O., Tawbi, H.A., van Akkooi, A., Testori, A., Carac`o, C., , Puzanov, and Perrone, F. The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018. 22588. 2019 J Transl Med (17):1.

Concepts Keywords
Adjuvant Cancer immunotherapy
Antigen Adjuvant therapy
Clinical Trials Targeted therapy
Counterpoint MEK inhibitor
Cytotoxic T Lymphocyte Antineoplastic drugs
Italy Immune system
Ligand Melanoma
Lymphocyte Cancer treatments
Melanoma Clinical medicine
Naples Medicine
Neoadjuvant Therapy Immunotherapy
Topical Neoadjuvant therapy
Clinical trials melanoma
Therapy melanoma

Semantics

Type Source Name
gene UNIPROT PDCD1
gene UNIPROT RPL17
gene UNIPROT CTSE
gene UNIPROT ZNHIT2
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Gold
gene UNIPROT FASTK
gene UNIPROT RAB8A
gene UNIPROT CYP27A1
gene UNIPROT LRP1
gene UNIPROT PMAIP1
gene UNIPROT RBM15
disease DOID carcinoma
disease MESH carcinoma
drug DRUGBANK Platinum
gene UNIPROT BRD2
gene UNIPROT SOAT1
gene UNIPROT PTS
gene UNIPROT EXOG
gene UNIPROT CXCL2
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
gene UNIPROT CA8
gene UNIPROT ANXA13
gene UNIPROT SPEN
gene UNIPROT ZNF746
gene UNIPROT POC1A
gene UNIPROT NAA50
pathway BSID Small cell lung cancer
disease MESH small cell lung cancer
disease DOID Cancer
disease MESH development
gene UNIPROT TBPL1
gene UNIPROT EFS
disease MESH overtreatment
disease MESH multiple
gene UNIPROT SNAP25
gene UNIPROT HERPUD1
gene UNIPROT CBARP
gene UNIPROT TLR9
disease DOID renal carcinoma
gene UNIPROT NR4A3
gene UNIPROT ARMC9
gene UNIPROT AKR1A1
gene UNIPROT TECR
gene UNIPROT DNER
gene UNIPROT GTF2IRD1
gene UNIPROT TNF
disease MESH dif
gene UNIPROT CD274
gene UNIPROT CTLA4
gene UNIPROT DEPP1
gene UNIPROT GOPC
gene UNIPROT SET
gene UNIPROT SLC35G1
drug DRUGBANK Dacarbazine
gene UNIPROT RBM8A
disease DOID NSCLC
gene UNIPROT LARGE1
gene UNIPROT ABCC8
gene UNIPROT LITAF
gene UNIPROT DNMT1
gene UNIPROT CD69
gene UNIPROT CD5L
gene UNIPROT TLR4
gene UNIPROT MS4A2
gene UNIPROT PHF11
disease MESH tumor
drug DRUGBANK Trametinib
drug DRUGBANK Dabrafenib
drug DRUGBANK Pembrolizumab
gene UNIPROT EMD
drug DRUGBANK Nivolumab
drug DRUGBANK Coenzyme M
disease MESH metastasis
gene UNIPROT KIDINS220
disease DOID cutaneous melanoma
gene UNIPROT MENT
drug DRUGBANK Trestolone
drug DRUGBANK Ipilimumab
disease MESH relapses
disease DOID noma
disease MESH noma
pathway BSID Reproduction
gene UNIPROT MAP2K7
gene UNIPROT BRAF
gene UNIPROT TNIP1
gene UNIPROT COL9A3
gene UNIPROT COMP
gene UNIPROT COL9A1
gene UNIPROT COL9A2
gene UNIPROT SCN8A
disease MESH death
pathway BSID Melanoma
disease MESH Melanoma
disease DOID Melanoma
gene UNIPROT RXFP2

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *